Gilead’s Remdesivir Wins FDA’s Orphan Drug Designation for COVID-19 Treatment
By Ruchi Jhonsa, Ph.D. While the clinical trials of this promising drug against SARS-CoV-2 are still on, the FDA has provided a significant advantage to Gilead’s remdesivir today. In an …
Read More